Back to News
Market Impact: 0.15
Perspective Therapeutics, Inc. Announces Interim Phase 1/2a Results for [212Pb]VMT-α-NET
Source: Nasdaq
Healthcare & Biotech
Perspective Therapeutics announced new interim results from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-expressing neuroendocrine tumors. The provided article text is truncated before the results or presentation details, so no efficacy, safety, or market implications can be assessed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Oncologists Cheer Melanoma Data
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- Investing.com’s stocks of the week
- Jefferies raises Zymeworks stock price target on Roche deal